Company has spent 2.0% of its operating revenues towards interest expenses and 8.5% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Orchid Pharma Share Price
Orchid Pharma Share Pri...
Orchid Pharma share price insights
Stock gave a 3 year return of 237.87% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)
Stock generated 237.87% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Orchid Pharma Ltd. share price moved up by 0.03% from its previous close of Rs 1,403.85. Orchid Pharma Ltd. stock last traded price is 1,404.20
Share Price Value Today/Current/Last 1,404.20 Previous Day 1,403.85
Key Metrics
PE Ratio (x) | 63.85 | ||||||||||
EPS - TTM (₹) | 21.99 | ||||||||||
MCap (₹ Cr.) | 7,121.98 | ||||||||||
Sectoral MCap Rank | 46 | ||||||||||
PB Ratio (x) | 6.09 | ||||||||||
Div Yield (%) | 0.00 | ||||||||||
Face Value (₹) | 10.00 | ||||||||||
Beta Beta
| 0.76 | ||||||||||
VWAP (₹) | 1,401.05 | ||||||||||
52W H/L (₹) |
Orchid Pharma Share Price Returns
1 Day | 0.03% |
1 Week | 1.83% |
1 Month | 2.27% |
3 Months | 36.54% |
1 Year | 157.25% |
3 Years | 237.87% |
5 Years | N.A. |
Orchid Pharma News & Analysis
NewsStocks in news: Vodafone Idea, Hindalco, Nykaa, Hero MotoCorp, Marico, Wipro
Disclosure Regarding The Order Passed By Goods And Service Tax Department
AnnouncementsChairman Speech- 31St Annual General Meeting Of Orchid Pharma Limited Held On August 21, 2024
AnnouncementsVoting Results For The 31St Annual General Meeting Of Orchid Pharma Limited
Announcements
Orchid Pharma Share Recommendations
Recent Recos
Current
Mean Recos by 3 Analysts
SellSellHoldBuyStrong
Buy
That's all for Orchid Pharma recommendations. Check out other stock recos.
Analyst Trends
Ratings | Current | 1 Week Ago | 1 Month Ago | 3 Months Ago |
---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 |
Hold | - | - | - | - |
Sell | - | - | - | - |
Strong Sell | - | - | - | - |
# Analysts | 3 | 3 | 3 | 3 |
Orchid Pharma Financials
Income (P&L)
Balance Sheet
Cash Flow
Ratios
Insights
Employee & Interest Expense
Company has spent 2.0% of its operating revenues towards interest expenses and 8.5% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Quarterly | Annual Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 251.98 230.46 228.21 207.11 184.81 Total Income Growth (%) 9.34 0.99 10.19 12.07 -12.67 Total Expenses 220.36 196.60 194.47 183.28 168.49 Total Expenses Growth (%) 12.08 1.10 6.10 8.78 21.90 EBIT 31.62 33.86 33.74 23.83 16.32 EBIT Growth (%) -6.61 0.36 41.58 46.00 -77.77 Profit after Tax (PAT) 29.35 32.96 29.43 19.80 9.40 PAT Growth (%) -10.94 11.97 48.62 110.57 -84.10 EBIT Margin (%) 12.55 14.69 14.78 11.51 8.83 Net Profit Margin (%) 11.65 14.30 12.90 9.56 5.09 Basic EPS (₹) 5.79 6.81 6.18 4.30 1.85 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 1,553.87 1,225.21 1,110.56 1,237.25 1,721.66 Total Assets Growth (%) 26.83 10.32 -10.24 -28.14 -44.05 Total Liabilities 384.41 536.56 463.18 584.34 697.30 Total Liabilities Growth (%) -28.36 15.84 -20.73 -16.20 -81.56 Total Equity 1,169.47 688.65 647.38 652.91 1,024.36 Total Equity Growth (%) 69.82 6.37 -0.85 -36.26 - Current Ratio (x) 3.04 1.35 1.87 3.87 3.25 Total Debt to Equity (x) 0.11 0.48 0.41 0.66 0.49 Contingent Liabilities 87.93 48.71 24.87 0.19 0.97 All figures in Rs Cr, unless mentioned otherwise
Insights
Increase in Cash from Investing
Company has used Rs 312.03 cr for investing activities which is an YoY increase of 899.65%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 125.99 18.34 92.47 23.59 80.80 Net Cash used in Investing Activities -312.03 -31.21 112.94 67.21 167.11 Net Cash flow from Financing Activities 167.04 31.17 -216.80 -164.99 -250.33 Net Cash Flow -19.00 18.29 -11.39 -74.20 -2.42 Closing Cash & Cash Equivalent 3.60 22.60 4.31 15.69 89.89 Closing Cash & Cash Equivalent Growth (%) -84.06 424.71 -72.56 -82.54 -2.62 Total Debt/ CFO (x) 1.07 18.07 2.90 18.25 6.21 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 7.88 6.72 -0.30 -17.84 -12.79 Return on Capital Employed (%) 8.37 5.65 -2.86 -4.00 -8.23 Return on Assets (%) 5.93 3.78 -0.17 -9.41 -7.61 Interest Coverage Ratio (x) 8.65 3.20 1.94 -0.86 -30.52 Asset Turnover Ratio (x) 0.59 0.57 0.48 36.37 29.50 Price to Earnings (x) 57.80 33.90 -625.00 -86.96 -0.16 Price to Book (x) 4.53 2.28 1.79 15.41 0.02 EV/EBITDA (x) 36.52 18.14 22.86 161.10 -350.31 EBITDA Margin (%) 17.27 15.47 11.10 14.44 -0.19
Orchid Pharma Peer Comparison
Orchid Pharma Stock Performance
Ratio Performance
Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 237.87% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 237.87% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Choose from Peers
Choose from Stocks
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 237.87% as compared to Nifty Midcap 100 which gave a return of 112.53%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 237.87% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
See All Parameters
MF Ownership
484.83
Amount Invested (in Cr.)
1.98%
% of AUM
0.00
% Change (MoM basis)
187.31
Amount Invested (in Cr.)
1.08%
% of AUM
0.00
% Change (MoM basis)
87.15
Amount Invested (in Cr.)
1.07%
% of AUM
-13.83
% Change (MoM basis)
MF Ownership as on 31 July 2024
Corporate Actions
Orchid Pharma Board Meeting/AGM
Orchid Pharma Dividends
- Others
Meeting Date Announced on Purpose Details Aug 12, 2024 Aug 06, 2024 Board Meeting Quarterly Results May 23, 2024 May 16, 2024 Board Meeting Audited Results Feb 08, 2024 Feb 02, 2024 Board Meeting Quarterly Results Nov 29, 2023 Oct 23, 2023 POM - Nov 04, 2023 Oct 30, 2023 Board Meeting Quarterly Results Type Dividend Dividend per Share Ex-Dividend Date Announced on Final 30% 3.0 Sep 13, 2012 May 15, 2012 Final 30% 3.0 Jul 19, 2011 May 18, 2011 Final 100% 10.0 Jul 12, 2010 May 28, 2010 Final 10% 1.0 Sep 17, 2009 Jun 30, 2009 Final 30% 3.0 Sep 18, 2008 May 29, 2008 All Types Ex-Date Record Date Announced on Details Bonus Sep 15, 2005 Sep 17, 2005 Jul 18, 2005 Bonus Ratio: 1 share(s) for every 2 shares held Rights Jan 09, 1995 Feb 01, 1995 Mar 15, 1995 Rights ratio: 1 share for every 1 held at a price of Rs 40.0
About Orchid Pharma
Orchid Pharma Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 7,121.98 Crore) operating in Pharmaceuticals sector. Orchid Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Materials, Sale of services and Other Operating Revenue for the year ending 31-Mar-2024. Show More
Executives
Auditors
- RG
Ram Gopal Agarwal
Chairman & Non-Exe.DirectorRGRam Gopal Agarwal
Chairman & Non-Exe.DirectorMDManish Dhanuka
Managing DirectorMDManish Dhanuka
Managing DirectorShow More - Singhi & Co.CNGSN & Associates LLP
Industry
Key Indices Listed on
-
Address
Plot Nos. 121-128, 128A-133, 138-151, 159-164,SIDCO Industrial Estate, Alathur,Chengalpattu, Tamil Nadu - 600110
More Details
Trending in Markets
Orchid Pharma Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.